Altimmune, Inc..
American biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 33
What's happening
Earlier this month
One to three months ago
-
Citigroup provided a stock rating for Altimmune, Inc.Some support1 report
-
Altimmune tests Pemvidutide for MASH treatment and plans FDA engagement, attracting attention from Goldman Sachs.Some support2 reports2 developments inside
-
Altimmune's Pemvidutide received Breakthrough Therapy Designation from the FDA.Some support2 reports
-
Altimmune, Inc. is seeking an End-of-Phase 2 meeting with the FDA regarding the results of pemvidutide trials for MASH.Some support2 reports
Gone quiet
No new reports in 90+ days-
MarketBeat aggregated analyst ratings for Altimmune, Inc., while Leerink Partners began coverage of the stock.Some support1 report
-
Mannatech and Altimmune, Inc. are listed on Nasdaq and operate across the Americas, Europe, Africa, and the Middle East.Some support1 report
-
Altimmune initiated the RESTORE Phase 2 trial.Speculative1 report
-
Altimmune, Inc. appointed Jerry Durso as Chairman of the board while developing therapeutics for MASH.Some support3 reports
-
BlackRock holds a 7.6% stake in Altimmune, Inc. as of August 13, 2025.Some support1 report
-
Altimmune, Inc.'s drug received Fast Track designation from the FDA on August 19, 2025. The WHO risk drinking level is a trial endpoint.Some support2 reports
-
Altimmune, Inc. participated in a conference in Boston on August 26, 2025.Some support1 report
-
Altimmune, Inc. held investor conferences in Miami Beach, FL, and New York, NY, on May 27, 2026.Some support1 report
-
Altimmune, Inc. presented data on pemvidutide for MASH at EASL Congress 2026, held in Barcelona, led by principal investigator Mazen Noureddin.Well supported4 reports
No events began in the chosen period. Widen it, or reset.
Around Altimmune, Inc. this week
News at the entities that move Altimmune, Inc. most-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves Altimmune, Inc.
-
Nasdaq StructuralOlenox Industries Inc. is headquartered in Texas and is publicly traded on the Nasdaq exchange. Michael McLaren serves as the company's Chairman and CEO.Moves Altimmune, Inc.
-
Scott Harris StructuralThe Alabama Department of Public Health has noted added demands on hospitals, with Scott Harris serving as State Health Officer.Moves Altimmune, Inc.
-
Citigroup Mentioned togetherMorgan Stanley reaffirmed an underweight rating and Citigroup restated a sell rating on Handelsbanken, reported by MarketBeat.Moves Altimmune, Inc.
-
Leerink partners Mentioned togetherLeerink Partners began coverage on Novogen Limited shares on October 20, 2026.Moves Altimmune, Inc.
-
Miami Beach Shared contextPamela Liebman reports on the current state and trends within the Miami Beach real estate market.Moves Altimmune, Inc.
Connections
The 15 strongest of 33, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nasdaq Structural
Altimmune, Inc. is formally listed and trades on the Nasdaq stock exchange.
-
FDA Structural
The FDA formally regulates Altimmune's drug development, granting designations like Fast Track and Breakthrough Therapy.
-
Scott Harris Structural
Scott Harris serves as the Chief Medical Officer of Altimmune, Inc.
-
mash Operational
Altimmune is actively developing and testing pemvidutide as a therapeutic approach for MASH disease.
-
Altimmune leverages the EASL platform by presenting its scientific data at their annual congress.
-
Miami Beach Shared context
Altimmune utilizes Miami Beach as the location for its investor conferences.
-
Citigroup Mentioned together
Citigroup provided a stock rating and analysis for Altimmune, Inc.
-
New York Shared context
Altimmune holds investor conferences in New York City, establishing a locational context for its operations.
Show all 15 connections
-
Mash Mentioned together
Both entities are mentioned in the context of developing therapeutics for MASH.
-
Amsterdam Shared context
Altimmune presented analyses at a congress held in Amsterdam.
-
MarketBeat Mentioned together
MarketBeat functions as a data aggregator, collecting and presenting analyst ratings concerning Altimmune's business performance.
-
Barcelona Shared context
Altimmune presented findings at a conference held in Barcelona.
-
Leerink partners Mentioned together
Leerink Partners began providing financial coverage and analysis of Altimmune's stock.
-
Gaithersburg Shared context
Altimmune, Inc. is located and operates within the geographical context of Gaithersburg.
-
JPEG Mentioned together
No evidence linking JPEG to Altimmune, Inc. was found in the provided timeline.
History
Events by the month they beganSeptember 2026
2 eventsJuly 2026
1 eventShow 1 earlier month
June 2026
10 events- Altimmune tests Pemvidutide for MASH treatment and plans FDA engagement, attracting attention from Goldman Sachs.
- MarketBeat aggregated analyst ratings for Altimmune, Inc., while Leerink Partners began coverage of the stock.
- Mannatech and Altimmune, Inc. are listed on Nasdaq and operate across the Americas, Europe, Africa, and the Middle East.
- Altimmune initiated the RESTORE Phase 2 trial.
- Altimmune, Inc. appointed Jerry Durso as Chairman of the board while developing therapeutics for MASH.
- BlackRock holds a 7.6% stake in Altimmune, Inc. as of August 13, 2025.
- Altimmune, Inc.'s drug received Fast Track designation from the FDA on August 19, 2025. The WHO risk drinking level is a trial endpoint.
- Altimmune, Inc. participated in a conference in Boston on August 26, 2025.
- Altimmune, Inc. held investor conferences in Miami Beach, FL, and New York, NY, on May 27, 2026.
- Altimmune, Inc. presented data on pemvidutide for MASH at EASL Congress 2026, held in Barcelona, led by principal investigator Mazen Noureddin.